The stock of Biolase Inc (NASDAQ: BIOL) has decreased by -13.23 when compared to last closing price of 0.17. Despite this, the company has experienced a -23.96% fall in its stock price over the last five trading sessions. Accesswire reported 2024-03-14 that LAKE FOREST, CA / ACCESSWIRE / March 14, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), the globally recognized leader in dental laser technology, today announced that it will release fourth quarter and full year 2023 financial and operating results on Thursday, March 21, 2024, after the close of the U.S. financial markets and will host a conference call and webcast that day at 4:30 p.m. ET / 1:30 p.m.
Is It Worth Investing in Biolase Inc (NASDAQ: BIOL) Right Now?
Additionally, the 36-month beta value for BIOL is 0.69. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for BIOL is 30.69M and currently, short sellers hold a 0.94% ratio of that float. The average trading volume of BIOL on April 09, 2024 was 5.50M shares.
BIOL’s Market Performance
BIOL’s stock has seen a -23.96% decrease for the week, with a 4.93% rise in the past month and a -86.52% fall in the past quarter. The volatility ratio for the week is 13.66%, and the volatility levels for the past 30 days are at 14.07% for Biolase Inc The simple moving average for the last 20 days is -7.61% for BIOL stock, with a simple moving average of -94.29% for the last 200 days.
Analysts’ Opinion of BIOL
Many brokerage firms have already submitted their reports for BIOL stocks, with The Benchmark Company repeating the rating for BIOL by listing it as a “Speculative Buy.” The predicted price for BIOL in the upcoming period, according to The Benchmark Company is $2 based on the research report published on June 19, 2019 of the previous year 2019.
Singular Research, on the other hand, stated in their research note that they expect to see BIOL reach a price target of $2.50. The rating they have provided for BIOL stocks is “Buy” according to the report published on April 25th, 2017.
WallachBeth gave a rating of “Hold” to BIOL, setting the target price at $2.50 in the report published on May 13th of the previous year.
BIOL Trading at -48.32% from the 50-Day Moving Average
After a stumble in the market that brought BIOL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.69% of loss for the given period.
Volatility was left at 14.07%, however, over the last 30 days, the volatility rate increased by 13.66%, as shares surge +13.88% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -82.69% lower at present.
During the last 5 trading sessions, BIOL fell by -23.96%, which changed the moving average for the period of 200-days by -98.09% in comparison to the 20-day moving average, which settled at $0.1599. In addition, Biolase Inc saw -86.91% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for BIOL
Current profitability levels for the company are sitting at:
- -0.36 for the present operating margin
- 0.34 for the gross margin
The net margin for Biolase Inc stands at -0.42. The total capital return value is set at -1.16. Equity return is now at value -888.93, with -56.30 for asset returns.
Based on Biolase Inc (BIOL), the company’s capital structure generated 1.01 points at debt to capital in total, while cash flow to debt ratio is standing at -0.82. The debt to equity ratio resting at -69.38. The interest coverage ratio of the stock is -7.6.
Currently, EBITDA for the company is -15.14 million with net debt to EBITDA at -0.72. When we switch over and look at the enterprise to sales, we see a ratio of 0.33. The receivables turnover for the company is 8.97for trailing twelve months and the total asset turnover is 1.4. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.26.
Conclusion
In conclusion, Biolase Inc (BIOL) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
